Discounted Cash Flow
Edwards Lifesciences Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $3.0b | $569.5m | $528.3m | 19.2% | $2.67 |
| 2017 | $3.4b (15.9%) | $583.6m (2.5%) | $832.6m (57.6%) | 17.0% (-11.6%) | $2.77 (3.7%) |
| 2018 | $3.7b (8.4%) | $722.2m (23.7%) | $688.1m (-17.4%) | 19.4% (14.2%) | $3.45 (24.5%) |
| 2019 | $4.3b (16.8%) | $1.0b (45.0%) | $925.0m (34.4%) | 24.1% (24.1%) | $5.03 (45.8%) |
| 2020 | $4.4b (0.9%) | $823.4m (-21.3%) | $647.3m (-30.0%) | 18.8% (-22.0%) | $1.32 (-73.8%) |
| 2021 | $5.2b (19.3%) | $1.5b (82.5%) | $1.4b (117.3%) | 28.7% (53.0%) | $2.41 (82.6%) |
| 2022 | $5.4b (2.9%) | $1.5b (1.3%) | $973.6m (-30.8%) | 28.3% (-1.6%) | $2.46 (2.1%) |
| 2023 | $6.0b (11.6%) | $1.4b (-7.9%) | $642.8m (-34.0%) | 23.4% (-17.4%) | $2.31 (-6.1%) |
| 2024 | $5.4b (-9.4%) | $4.2b (197.7%) | $289.9m (-54.9%) | 76.7% (228.6%) | $6.98 (202.2%) |
| 2025 | $6.1b (11.5%) | $1.1b (-74.3%) | $1.3b (360.5%) | 17.7% (-76.9%) | $1.84 (-73.6%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.